Hostname: page-component-89b8bd64d-j4x9h Total loading time: 0 Render date: 2026-05-08T06:56:58.789Z Has data issue: false hasContentIssue false

Intermittent fasting with a high-protein diet mitigated osteoarthritis symptoms by increasing lean body mass and reducing inflammation in osteoarthritic rats with Alzheimer’s disease-like dementia

Published online by Cambridge University Press:  10 March 2021

Sunmin Park*
Affiliation:
Department of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, 165 Sechul-Ri, BaeBang-Yup, ChungNam-Do, 336-795 Asan-Si, South Korea
*
*Corresponding author: Sunmin Park, email smpark@hoseo.edu
Rights & Permissions [Opens in a new window]

Abstract

Menopausal women are susceptible to osteoarthritis(OA) and memory impairment. We hypothesised that Alzheimer’s-like disease(AD) exacerbates OA and that intermittent fasting(IMF) with a high-protein(H-P) diet would enhance memory function and relieve OA symptoms in oestrogen-deficient animals induced AD and OA. The action mechanism was also explored. Ovariectomised Sprague–Dawley rats were fed high-fat(H-F) or H-P diets for 2 weeks, and then they had a hippocampal infusion of β-amyloid(25–35) for 4 weeks to induce AD and an injection of monoidoacetate(MIA) into the articular cartilage to induce OA. Non-AD groups had non-AD symptoms by hippocampal amyloid-β(35–25) infusion. IMF suppressed memory impairment in AD rats, especially those fed H-P diets. Compared with non-AD, AD exacerbated OA symptoms, including swelling, limping, slowed treadmill running speed, and uneven weight distribution in the left leg. The exacerbations were linked to increased inflammation and pain, but IMF and H-P lessened the exacerbation. Lean body mass(LBM) decreased with AD, but H-P protected against LBM loss. Histological examination of the knee joint revealed the degree of the cellular invasion into the middle zone, and the changes in the tidemark plateau were greatest in the AD-AL with H-F, while non-AD-IMF improved the cellular invasion to as much as non-AD-AL. H-P reduced the infiltration into the middle zone of the knee and promoted collagen production. In conclusion, AD exacerbated the articular cartilage deterioration and memory impairment, and IMF with H-P alleviated the memory impairment and osteoarthritic symptoms by decreasing hippocampal amyloid-β deposition and proinflammatory cytokine expressions and by increasing LBM.

Information

Type
Full Papers
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Nutrition Society
Figure 0

Fig. 1. Experimental design and grouping. All seventy-two rats had body composition measurements by dual-energy X-ray absorptiometry (DEXA), and they had ovariectomy (OVX). After all the rats had OVX, they were then randomly divided into six groups of twelve each. They consumed their assigned diets and followed their feeding methods for 2 weeks before AD and osteoarthritis induction, and then they had simultaneous AD and osteoarthritis inductions. They continued to receive their assigned diet feeding protocols for additional 4 weeks. Meanwhile, osteoarthritis symptoms were evaluated by observation of behaviours, running speed on a treadmill and weight distribution in the left leg every week. A glucose intolerance test was also assessed for glucose metabolism at the 6th week. Memory impairment was also determined by water maze, passive avoidance and Y maze at the 6th week. At the end of the experiment, all rats had DEXA scans for body composition determination. They were then randomly divided into six groups of twelve each: (1) AD-AL-F: hippocampal amyloid-β(25–35) infusion (AD) + ad libitum feeding (AL) + a high-fat diet (F), (2) AD-IMF-F: AD + intermittent fasting feeding (IMF) + F, (3) AD-AL-P: AD + AL + a high-protein diet (P), (4) AD-IMF-P: AD + IMF + P, (5) non-AD-AL-F: ICV amyloid-β(35–25) infusion (non-AD) + AL + F and (6) non-AD-AL-P: non-AD + AL + P.

Figure 1

Table 1. Body weight, visceral fat mass, serum 17β-oestradiol concentrations and tail skin temperature(Mean values and standard deviations, n 12 for each group)

Figure 2

Table 2. Metabolic parameters related to osteoarthritis symptoms(Mean values and standard deviations, n 12 for each group)

Figure 3

Fig. 2. Body composition of femur and knee with intra-articular injection of monoiodoacetate (MIA) at days 0 and 21 after an intra-articular injection of monoiodoacetate. (a) The differences in bone mineral density (BMD) in the lumbar spine, osteoarthritis (OA)-leg, and non-OA-leg before and after diet treatments. (b) The differences in lean body mass in the hip, OA-leg and non-OA-leg before and after diet treatments. (c) The differences in fat mass in the abdomen, OA-leg and non-OA-leg before and after diet treatments. Each data point and error bar represent the mean values and standard deviations from twelve rats per group. *Significant treatment effect among the groups by two-way ANOVA test by IMF at P < 0·05. †Significant treatment effect among the groups by two-way ANOVA test by dietary protein at P < 0·05. ‡Significant treatment effect among the groups by AD at P < 0·05. §Significance with dietary protein in non-AD groups by two-way ANOVA at P < 0.05. , AD-AL-F; , AD-AL-P; , AD-IMF-F; , AD-IMF-P; , non-AD-AL-F; , non-AD-AL-P. AD, hippocampal amyloid-β(25–35) infusion; AL, ad libitum feeding; F, high-fat diet; P, high-protein diet; IMF, intermittent fasting; non-AD, ICV amyloid-β(35–25) infusion.

Figure 4

Fig. 3. Memory deficit of rats with an amyloid-β infusion. (a) The frequencies to visit the zone where the platform was located; duration to stay in the zone; the latency to visit the zone during a water maze test. (b) Latency time to enter the dark room in passive avoidance test and the number of the right turn in total turns in a Y maze test. Each data point and error bar represent the mean values and standard deviations from twelve rats per group. *Significant IMF effect among the AD groups by two-way ANOVA test at P < 0·05. Significant AD effect among AL treatment groups by one-way ANOVA at P < 0·05. , AD-AL-F; , AD-AL-P; , AD-IMF-F; , AD-IMF-P; , non-AD-AL-F; , non-AD-AL-P. AD, hippocampal amyloid-β(25–35) infusion; AL, ad libitum feeding; F, high-fat diet; P, high-protein diet; IMF, intermittent fasting; non-AD, ICV amyloid-β(35–25) infusion.

Figure 5

Fig. 4. Gross observation of osteoarthritis symptoms and pain-related behaviours at 3, 7, 14 and 21 d after an intra-articular injection of monoiodoacetate (MIA). (a) Oedema scores. (b) Limping scores. (c) The maximum velocity in treadmills. (d) Weight distribution between MIA- and saline-injected legs. Each data point and error bar represent the mean values and standard deviations from twelve rats per group. *Significant IMF effect among the AD groups by two-way ANOVA test at P < 0·05. †Significant dietary protein effect among the AD groups by two-way ANOVA test at P < 0·05. Significant AD effect among AL treatment groups by one-way ANOVA at P < 0·05. , AD-AL-F; , AD-AL-P; , AD-IMF-F; , AD-IMF-P; , non-AD-AL-F; , non-AD-AL-P. AD, hippocampal amyloid-β(25–35) infusion; AL, ad libitum feeding; F, high-fat diet; P, high-protein diet; IMF, intermittent fasting; non-AD, ICV amyloid-β(35–25) infusion.

Figure 6

Fig. 5. The histopathological features of osteoarthritic lesions and the mRNA expression of matrix metalloproteinases (MMP) and proinflammatory cytokines in the articular cartilage at 28 d after an intra-articular injection of monoiodoacetate (MIA) (a) The damage to articular cartilage damage and subchondral bone in haematoxylin–eosin stain (magnifying power 100× and 200×). Red arrows indicated the damage extent of the articular cartilage. (b) The proteoglycan loss in the joint and extent of the tibial plateau in Safranin O–fast green stain (magnifying power 100×). (c) mRNA expression of MMP-3, MMP-13, TNF-α, IL-1β and IL-6 in the articular cartilage. Each data point and error bar represent the mean values and standard deviations from six rats per group. *Significant IMF effect among the AD groups by two-way ANOVA test at P < 0·05. Significant dietary protein effect among the AD groups by two-way ANOVA test at P < 0·05. Significant AD effect among AL treatment groups by one-way ANOVA at P < 0·05. § Significant dietary protein effect among AL treatment groups by one-way ANOVA at P < 0·05. , AD-AL-F; , AD-AL-P; , AD-IMF-F; , AD-IMF-P; , non-AD-AL-F; , non-AD-AL-P. AD, hippocampal amyloid-β(25–35) infusion; AL, ad libitum feeding; F, high-fat diet; P, high-protein diet; IMF, intermittent fasting; non-AD, ICV amyloid-β(35–25) infusion.